Skip to main content
SpringerLink
Log in

The Achievement of a Sustained Virological Response Either Before or After Hepatectomy Improves the Prognosis of Patients with Primary Hepatitis C Virus-Related Hepatocellular Carcinoma

  • Hepatobiliary Tumors
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

Hepatitis C virus (HCV) infection is a major cause of hepatocellular carcinoma (HCC). Achieving a sustained virological response (SVR) is associated with a reduced risk of recurrence. The recent introduction of direct acting antivirals (DAAs) has resulted in SVR rates of nearly 100% in treated patients. The purpose of the present study was to clarify the outcomes in patients who underwent antiviral therapy and patients without antiviral therapy.

Methods

This retrospective study included 220 patients with primary HCV-related HCC who underwent hepatectomy. An SVR was defined as a serum HCV-RNA titer below the detection sensitivity limit at 6 months after the termination of antiviral therapy. Postoperative antiviral therapy was introduced after confirming that there was no early recurrence.

Results

Eighty-eight patients received antiviral therapy. Among these, 58 patients (66%) obtained an SVR. With the exception of one patient, all patients who received DAAs obtained an SVR. The overall survival rate of the pre-operative SVR group was significantly better than that of the preoperative untreated group (P = 0.045). Moreover, there was no recurrence at 3 years after surgery in the pre-operative SVR group. The achievement of an SVR was an independent predictor of overall survival [hazard ratio (HR) 0.75, 95% confidence interval (CI) 0.59–0.94, P = 0.011] and recurrence (HR 0.61, 95% CI 0.40–0.94, P = 0.024).

Conclusions

Obtaining an SVR either before or after surgery was associated with the suppression of HCC recurrence after hepatectomy in patients with primary HCV-related HCC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Vital statistics, Ministry of Health, Labour and Welfare. http://www.mhlw.go.jp/english/database/db-hw/vs01.html. Accessed 25 Sep 2017.

  2. Kudo M, Izumi N, Sakamoto M, et al. Liver Cancer Study Group of Japan. Survival analysis over 28 years of 173,378 patients with hepatocellular carcinoma in Japan. Liver Cancer. 2016;5:190–7.

  3. Shim JH, Jun MJ, Han S, et al. Prognostic nomograms for prediction of recurrence and survival after curative liver resection for hepatocellular carcinoma. Ann Surg. 2015;261:939–46.

    Article  Google Scholar 

  4. Chapman WC, Klintmalm G, Hemming A, et al. Surgical treatment of hepatocellular carcinoma in North America: can hepatic resection still be justified? J Am Coll Surg. 2015;220:628–37.

    Article  Google Scholar 

  5. Yamamoto T, Kajino K, Kudo M, Sasaki Y, Arakawa Y, Hino O. Determination of the clonal origin of multiple human hepatocellular carcinomas by cloning and polymerase chain reaction of the integrated hepatitis B virus DNA. Hepatology. 1999;29:1446–52.

    Article  CAS  Google Scholar 

  6. Yasui M, Harada A, Nonami T, et al. Potentially multicentric hepatocellular carcinoma: clinicopathologic characteristics and postoperative prognosis. World J Surg. 1997;21:860–4.

    Article  CAS  Google Scholar 

  7. Matsuda M, Fujii H, Kono H, Matsumoto Y. Surgical treatment of recurrent hepatocellular carcinoma based on the mode of recurrence: repeat hepatic resection or ablation are good choices for patients with recurrent multicentric cancer. J Hepatobiliary Pancreat Surg. 2001;8:353–9.

    Article  CAS  Google Scholar 

  8. Arii S, Monden K, Niwano M, et al. Results of surgical treatment for recurrent hepatocellular carcinoma; comparison of outcome among patients with multicentric carcinogenesis, intrahepatic metastasis, and extrahepatic recurrence. J Hepatobiliary Pancreat Surg. 1998;5:86–92.

    Article  CAS  Google Scholar 

  9. Imamura H, Matsuyama Y, Tanaka E, et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol. 2003;38:200–7.

    Article  Google Scholar 

  10. Mazzaferro V, Romito R, Schiavo M, et al. HCC Italian Task Force. Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology. 2006;44:1543–54.

  11. Shinkawa H, Hasegawa K, Arita J, et al. Impact of sustained virological response to interferon therapy on recurrence of hepatitis C virus-related hepatocellular carcinoma. Ann Surg Oncol. 2017;24:3196–202.

    Article  Google Scholar 

  12. Koda M, Tanaka S, Takemura S, et al. Long-term prognostic factors after hepatic resection for hepatitis C virus-related hepatocellular carcinoma, with a special reference to viral status. Liver Cancer. 2018;7:261–76.

    Article  Google Scholar 

  13. Conti F, Buonfiglioli F, Scuteri A, et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol. 2016;65:727–33.

    Article  CAS  Google Scholar 

  14. Reig M, Mariño Z, Perelló C, et al. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J Hepatol. 2016;65:719–26.

    Article  CAS  Google Scholar 

  15. Kozbial K, Moser S, Schwarzer R, et al. Unexpected high incidence of hepatocellular carcinoma in cirrhotic patients with sustained virologic response following interferon-free directacting antiviral treatment. J Hepatol. 2016;65:856–8.

    Article  Google Scholar 

  16. Cardoso H, Vale AM, Rodrigues S, et al. High incidence of hepatocellular carcinoma following successful interferon-free antiviral therapy for hepatitis C associated cirrhosis. J Hepatol. 2016;65:1070–1.

    Article  Google Scholar 

  17. ANRS collaborative study group on hepatocellular carcinoma (ANRS CO22 HEPATHER, CO12 CirVir and CO23 CUPILT cohorts). Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: data from three ANRS cohorts. J Hepatol. 2016;65:734–40.

  18. Torres HA, Vauthey JN, Economides MP, Mahale P, Kaseb A. Hepatocellular carcinoma recurrence after treatment with directacting antivirals: first, do no harm by withdrawing treatment. J Hepatol. 2016;65:862–4.

    Article  Google Scholar 

  19. Minami T, Tateishi R, Nakagomi R, et al. The impact of directacting antivirals on early tumor recurrence after radiofrequency ablation in hepatitis C-related hepatocellular carcinoma. J Hepatol. 2016;65:1272–3.

    Article  CAS  Google Scholar 

  20. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the esophagus for bleeding oesophageal varices. Br J Surg. 1973;60:646–9.

    Article  CAS  Google Scholar 

  21. Liver Cancer Study Group of Japan General rules for the clinical and pathological study of primary liver cancer, 2008. 5th Japanese ed. Tokyo: Kanehara; 2008.

  22. Sobin LH, Gospodarowicz MK, Wittekind CH, editors. TNM Classification of Malignant Tumours, 7th ed. New York: Wiley-Liss; 2009.

    Google Scholar 

  23. Okamura Y, Ito T, Sugiura T, Mori K, Uesaka K. Anatomic versus nonanatomic hepatectomy for a solitary hepatocellular carcinoma: a case-controlled study with propensity score matching. J Gastrointest Surg. 2014;18:1994–2002.

    Article  Google Scholar 

  24. Strasberg SM. Nomenclature of hepatic anatomy and resections: a review of the Brisbane 2000 system. J Hepatobiliary Pancreat Surg. 2005;12:351–5.

    Article  Google Scholar 

  25. Kumada T, Nakano S, Takeda I, et al. Patterns of recurrence after initial treatment in patients with small hepatocellular carcinoma. Hepatology. 1997;25:87–92.

    Article  CAS  Google Scholar 

  26. Poon RT, Fan ST, Ng IO, Lo CM, Liu CL, Wong J. Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. Cancer. 2000;89:500–7.

    Article  CAS  Google Scholar 

  27. Ikeda K, Arase Y, Saitoh S, et al. Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor: a prospective randomized study of hepatitis C virus-related liver cancer. Hepatology. 2000;32:228–32.

    Article  CAS  Google Scholar 

  28. Ikeda K, Kawamura Y, Kobayashi M, et al. Direct-acting antivirals decreased tumor recurrence after initial treatment of hepatitis C virus-related hepatocellular carcinoma. Dig Dis Sci. 2017;62:2932–42.

    Article  CAS  Google Scholar 

Download references

Funding

There are no grants or other financial support for this study.

Author information

Authors and Affiliations

  1. Division of Hepato-Biliary-Pancreatic Surgery, Shizuoka Cancer Center Hospital, Sunto-Nagaizumi, Shizuoka, Japan

    Yukiyasu Okamura MD, Teiichi Sugiura MD, Takaaki Ito MD, Yusuke Yamamoto MD, Ryo Ashida MD, Katsuhisa Ohgi MD & Katsuhiko Uesaka MD

Authors
  1. Yukiyasu Okamura MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Teiichi Sugiura MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Takaaki Ito MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yusuke Yamamoto MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ryo Ashida MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Katsuhisa Ohgi MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Katsuhiko Uesaka MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yukiyasu Okamura MD.

Ethics declarations

Disclosure

The authors declare that there have no conflicts of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Okamura, Y., Sugiura, T., Ito, T. et al. The Achievement of a Sustained Virological Response Either Before or After Hepatectomy Improves the Prognosis of Patients with Primary Hepatitis C Virus-Related Hepatocellular Carcinoma. Ann Surg Oncol 26, 4566–4575 (2019). https://doi.org/10.1245/s10434-019-07911-w

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-019-07911-w

Search

Navigation